. . "Vliv agonisty mGLU 2/3 receptor\u016F LY379268 na chov\u00E1n\u00ED v ketaminov\u00E9m modelu psych\u00F3zy"@cs . "C\u00EDlem t\u00E9to pr\u00E1ce bylo zhodnotit vliv agonismu mGlu2/3 receptor\u016F na zm\u011Bny v chov\u00E1n\u00ED potkana v anim\u00E1ln\u00EDm modelu psych\u00F3zy. Anim\u00E1ln\u00ED modely psych\u00F3z vyvolan\u00E9 aplikac\u00ED NMDA antagonist\u016F jsou v sou\u010Dasnosti nejroz\u0161\u00ED\u0159en\u011Bj\u0161\u00EDmi modely, kter\u00E9 se pou\u017E\u00EDvaj\u00ED k testov\u00E1n\u00ED antipsychotick\u00E9ho potenci\u00E1lu l\u00E1tek. Agonist\u00E9 mGLU2/3 receptor\u016F jsou v sou\u010Dasn\u00E9 dob\u011B nov\u00FDm mo\u017En\u00FDm sm\u011Brem v l\u00E9\u010Db\u011B schizofrenie. V na\u0161em experiment\u00E1ln\u00EDm uspo\u0159\u00E1d\u00E1n\u00ED jsme hodnotili vliv agonisty mGlu2/3 receptor\u016F, l\u00E1tky LY379268 (3 mg/kg i.p.), na zm\u011Bnu v lokomoci potkana a deficitu v senzorimotorick\u00E9m zpracov\u00E1n\u00ED informac\u00ED po pod\u00E1n\u00ED NMDA antagonisty ketaminu. Uk\u00E1zali jsme, \u017Ee ketamin vede k rozvoji hyperlokomoce a sou\u010Dasn\u011B naru\u0161uje prepulzn\u00ED inhibici \u00FAlekov\u00E9 reakce (model pozitivn\u00EDch p\u0159\u00EDznak\u016F a poruchy zpracov\u00E1n\u00ED informac\u00ED u schizofrenie). Samotn\u00E1 aplikace LY379268 zp\u016Fsob\u00ED hypolokomoci, zv\u00FD\u0161en\u00ED vlastn\u00ED \u00FAlekov\u00E9 reakce a k po\u0161kozen\u00ED prepulzn\u00ED inhibici \u00FAlekov\u00E9 reakce. V kombinaci s ketaminem, LY379268 m\u00EDrn\u011B sni\u017Eovalo hyperlokomoci a nem\u011Blo vliv na deficit v p" . "RIV/00023752:_____/09:00000955!RIV10-MZ0-00023752" . "Hor\u00E1\u010Dek, Ji\u0159\u00ED" . "6"^^ . . . "The goal of this study was to evaluate the influence of mGlu2/3 receptor agonism on the behavior of rats in the animal model of psychosis. The animal model of psychosis induced through the application of NMDA antagonists is currently the most widely used model in the assessment of substances? antipsychotic potential. Agonists of mGlu2/3 receptors currently offer a potentially new direction in the treatment of schizophrenia. The present study was structured to evaluate the effects of mGlu2/3 receptor agonist LY379268 (3 mg/kg i.p.) on changes in the locomotion of rats and the deficit of sensorimotor information processing after administration of the NMDA antagonist ketamine. We demonstrated that ketamin leads to the development of hyperlocomotion and concurrently interrupts the prepulse inhibition of the startle reflex response (in line with the model of positive symptomatology and disruption of information processing in schizophrenia). Application of LY379268 alone leads to hyperlocomotion, increased"@en . "Vliv agonisty mGLU 2/3 receptor\u016F LY379268 na chov\u00E1n\u00ED v ketaminov\u00E9m modelu psych\u00F3zy" . . . "P\u00E1len\u00ED\u010Dek, Tom\u00E1\u0161" . . "349141" . "CZ - \u010Cesk\u00E1 republika" . "1211-7579" . . "Psychiatrie" . . . "4"^^ . . . "4" . . . . . "The effect mGlu2/3 receptor agonist LY379268 on behavior in ketamine-induced model of psychoses"@en . "Fuj\u00E1kov\u00E1, Michaela" . . . "Nov\u00E1k, Tom\u00E1\u0161" . "Buben\u00EDkov\u00E1-Vale\u0161ov\u00E1, V\u011Bra" . . "P(1M0517), P(NS10375)" . "RIV/00023752:_____/09:00000955" . . "[73960895A53D]" . "Vliv agonisty mGLU 2/3 receptor\u016F LY379268 na chov\u00E1n\u00ED v ketaminov\u00E9m modelu psych\u00F3zy"@cs . . "13" . . "ketamin; LY379268; rat; animal model; schizophrenia; locomotion; prepulse inhibition of the startle reflex response"@en . "C\u00EDlem t\u00E9to pr\u00E1ce bylo zhodnotit vliv agonismu mGlu2/3 receptor\u016F na zm\u011Bny v chov\u00E1n\u00ED potkana v anim\u00E1ln\u00EDm modelu psych\u00F3zy. Anim\u00E1ln\u00ED modely psych\u00F3z vyvolan\u00E9 aplikac\u00ED NMDA antagonist\u016F jsou v sou\u010Dasnosti nejroz\u0161\u00ED\u0159en\u011Bj\u0161\u00EDmi modely, kter\u00E9 se pou\u017E\u00EDvaj\u00ED k testov\u00E1n\u00ED antipsychotick\u00E9ho potenci\u00E1lu l\u00E1tek. Agonist\u00E9 mGLU2/3 receptor\u016F jsou v sou\u010Dasn\u00E9 dob\u011B nov\u00FDm mo\u017En\u00FDm sm\u011Brem v l\u00E9\u010Db\u011B schizofrenie. V na\u0161em experiment\u00E1ln\u00EDm uspo\u0159\u00E1d\u00E1n\u00ED jsme hodnotili vliv agonisty mGlu2/3 receptor\u016F, l\u00E1tky LY379268 (3 mg/kg i.p.), na zm\u011Bnu v lokomoci potkana a deficitu v senzorimotorick\u00E9m zpracov\u00E1n\u00ED informac\u00ED po pod\u00E1n\u00ED NMDA antagonisty ketaminu. Uk\u00E1zali jsme, \u017Ee ketamin vede k rozvoji hyperlokomoce a sou\u010Dasn\u011B naru\u0161uje prepulzn\u00ED inhibici \u00FAlekov\u00E9 reakce (model pozitivn\u00EDch p\u0159\u00EDznak\u016F a poruchy zpracov\u00E1n\u00ED informac\u00ED u schizofrenie). Samotn\u00E1 aplikace LY379268 zp\u016Fsob\u00ED hypolokomoci, zv\u00FD\u0161en\u00ED vlastn\u00ED \u00FAlekov\u00E9 reakce a k po\u0161kozen\u00ED prepulzn\u00ED inhibici \u00FAlekov\u00E9 reakce. V kombinaci s ketaminem, LY379268 m\u00EDrn\u011B sni\u017Eovalo hyperlokomoci a nem\u011Blo vliv na deficit v p"@cs . "Vliv agonisty mGLU 2/3 receptor\u016F LY379268 na chov\u00E1n\u00ED v ketaminov\u00E9m modelu psych\u00F3zy" . . . "The effect mGlu2/3 receptor agonist LY379268 on behavior in ketamine-induced model of psychoses"@en . . "Gorman, Ingmar" . "6"^^ .